3- V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and metabolic diseases, announced today that it will present data from its ongoing Phase 1 clinical study of TVB-2640 in solid tumor patients at the AACR annual meeting in Washington, D.C. The abstract "First in human study of the first-in-class
BlackBerry shares rose 0.86 percent to $7.01 in after-hours trading. Akari Therapeutics PLC disclosed that the FDA has granted Fast Track designation for Coversin. Akari Therapeutics shares climbed 8.11 percent to $7.55 in the after-hours trading session. Analysts are expecting Sorl Auto Parts, Inc. to have earned $0.19 per share on revenue of $64.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced Michael J. Yang has joined ACADIA as Executive Vice President and Chief Commercial Officer. Mr. Yang succeeds Terrence O. Moore, who has
Henry Brem, Director of the Neurosurgery Department at Johns Hopkins University. Henry Brem who built one of the largest brain tumor research and treatment centers in the world at Johns Hopkins University. Dr. Brem is a pioneer in the development of local drug delivery treatments, and invented and developed Gliadel which is a FDA approved, local
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Zileuton Extended Release Tablets, 600 mg.
By a News Reporter-Staff News Editor at Health& Medicine Week Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced the successful completion of its reverse merger transaction with Aerpio Therapeutics, Inc. and Aerpio Acquisition Corp., a wholly-owned subsidiary of
LONDON- Aeterna Zentaris Inc. is gearing up to file a new drug application seeking approval of Macrilen for the evaluation of growth hormone deficiency in adults in the third quarter of this year. This compound carries orphan drug designation of the FDA for diagnosis of growth hormone deficiency in adults. Akari Therapeutics' investigational drug C
-Madison, Wis. Cellectar Biosciences, Inc., an oncology-focused clinical stage biotechnology company, today announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate CLR 131 in patients with multiple myeloma and other hematologic malignancies. Cellectar will receive approximately $2 million in a non-dilutive gran
By a News Reporter-Staff News Editor at Drug Week Agilent Technologies Inc. has received a 2017 Scientists' Choice Award- Best Webinar Series of the Year- for its Biopharmaceuticals Webinar Series titled Solutions in Biopharmaceutical Discovery and Development, which ran for 10 episodes over the course of 2016. "We were delighted to present Agil
-Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug Administration has granted Fast Track designation for Coversin for treatment of paroxysmal nocturnal hemoglobinuria in patients who have polymorphisms conferring eculizumab resistance. Gur Roshwalb, Chief Executive Officer...
Akari Therapeutics PLC shares are trading higher by $3.40 at $10.40 in Friday's session.The catalyst for the rally is a report that the company has received FDA fast track designation for the Coversin. On Thursday, before the announcement, the stock added $0.33 from $6.65 to $6.98 on one of its biggest volume days in years. After a higher open, it
By a News Reporter-Staff News Editor at Drug Week Alkermes plc announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate prodrug candidate in development for the treatment of relapsing forms of multiple sclerosis. The company plans to submit a New Drug Application for ALKS 8700 for the treatment of RRMS to th
By a News Reporter-Staff News Editor at Genomics& Genetics Weekly- Allergan plc, a leading global pharmaceutical company, and Editas Medicine, Inc., a leading genome editing company, announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited, and Editas Medicine have entered into a strategic research and...
Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President will be presenting at the 16 th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 12:50 p.m. Eastern Time in New York, NY.. The Amphastar Pharmaceuticals logo and other trademarks or service marks of Amphastar Pharmaceuticals, Inc., including, but
Amryt Pharma, the orphan drug development company that was subject to a reverse takeover by former oil and gas group Fastnet last year, posted 1.35 million of sales last year. Amryt, led by chief executive Joe Wiley, secured exclusive rights in December to market US-based Aegerion Pharmaceuticals drug called Lojuxta, which is used to treat disorder
Analyst Ratings For CytomX Therapeutics (NASDAQ:CTMX) Today, Cann reiterated its Hold rating on CytomX Therapeutics (NASDAQ:CTMX). There are 1 sell rating, 2 hold ratings, 3 buy ratings on the stock. The current consensus rating on CytomX Therapeutics (NASDAQ:CTMX) is Hold (Score: 2.33) with a consensus target price of $28.00 per share, a potential
Analyst Ratings For Alder Biopharmaceuticals (NASDAQ:ALDR) Today, Jefferies Group LLC reiterated its Buy rating on Alder Biopharmaceuticals (NASDAQ:ALDR) with a price target of $43.00. There are 9 buy ratings on the stock. The current consensus rating on Alder Biopharmaceuticals (NASDAQ:ALDR) is Buy (Score: 3.00) with a consensus target price of $4
Analyst Ratings For Acorda Therapeutics (NASDAQ:ACOR) Today, Stifel Nicolaus reiterated its Buy rating on Acorda Therapeutics (NASDAQ:ACOR) with a price target of $30.00. There are 3 hold ratings, 6 buy ratings on the stock. The current consensus rating on Acorda Therapeutics (NASDAQ:ACOR) is Buy (Score: 2.67) with a consensus target price of $33.8
You should read the following discussion and analysis together with the financial statements and the related notes to those statements included elsewhere in this report. The accompanying Management's Discussion and Analysis of Financial Condition and Results of Operations gives effect to the restatement adjustments made to the previously reported..
-Topline data from the study expected in second half of 2018- 31 March 2017 Breda, the Netherlands/ Ghent, Belgium- argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the dosing of the first patient in a Phas
Argenx announced the dosing of the first patient in a Phase II proof-of-concept study for ARGX-113 in patients with primary immune thrombocytopenia. As quoted in the press release:. The initiation of the second Phase II trial for our lead candidate, ARGX-113, is an important milestone for the company as it exemplifies the breadth of potential th
Jeff Merkley, D- Ore., issued the following news release:. In the wake of Congressional Republicans' failed attempt to rip health coverage away from millions of Americans, U.S. Senator Al Franken and a key group of Senate Democrats launched a major push to improve the Affordable Care Act by bringing down the skyrocketing price of prescription drugs
WASHINGTON, DC- In the wake of Congressional Republicans' failed attempt to rip health coverage away from millions of Americans, U.S. Senators Jack Reed and Sheldon Whitehouse have joined Al Franken and a key group of Senate Democrats to launch a major push to improve the Affordable Care Act by bringing down the skyrocketing price of prescription d
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company has updated the time for its conference call and webcast on Monday, April 3 during ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florid
Release date- 29032017- AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Medicines Agency has granted orphan designation to inebilizumab for the treatment of neuromyelitis optica spectrum disorder. Developed by MedImmune, inebilizumab is currently in Phase IIb clinical development for..